MedCity News November 3, 2021
Not all drugs will be subject to price negotiation under the revised legislation. But the agreement sets up a framework enabling Medicare to negotiate the prices of medicines that have been on the market for a long time, and also caps the monthly price of insulin, which has been a flashpoint of drug price debate.
A proposal to allow Medicare to negotiate with pharmaceutical companies over drug prices is back in the massive infrastructure bill being drafted by Congress. The provision was nixed from an earlier draft of the legislation last week. But Democratic leaders have reached a “compromise” that gives Medicare some authority to negotiate prices for certain high-cost prescription drugs.
Insulin, one of the highest profile drugs due...
Today's Sponsors
Today's Sponsor